- Home
- KPRX vs FTFT Comparison
KPRX vs FTFT Comparison
Compare KPRX & FTFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPRX | FTFT |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 7.5M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | KPRX | FTFT |
|---|---|---|
| Price | $2.09 | $1.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 40.6K | 22.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,158,125.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.76 | $0.17 |
| 52 Week High | $4.18 | $4.03 |
Technical Indicators
Market Signals| Indicator | KPRX | FTFT |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 44.67 |
| Support Level | $2.01 | $1.32 |
| Resistance Level | $2.23 | $1.74 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 50.00 | 20.80 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.